Endovascular Repair of Descending Thoracic Aortic Aneurysms
This study has been completed.
Sponsor:
Stanford University
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00802984
First received: December 4, 2007
Last updated: December 12, 2008
Last verified: December 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether the system is safe and effective for the intended use of treating descending thoracic aortic aneurysms.
| Condition | Intervention | Phase |
|---|---|---|
|
Aortic Aneurysm, Thoracic |
Device: Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Endovascular Treatment of Thoracic Aortic Aneurysms Using the TALENT Stent Graft System |
Resource links provided by NLM:
Further study details as provided by Stanford University:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient is a candidate for repair of a descending thoracic aortic aneurysm.
Patient has one or more of the following:
- Descending thoracic aneurysm, 5 cm in diameter or greater with proximal and distal neck suitable for stent graft placement.
- Aneurysm is 4-5 cm in diameter but has increased in size by 0.5 cm in last 6 months.
- Maximum diameter of aneurysm exceeds one and one-half times the transverse dimension of an adjacent normal aortic segment.
- Post-traumatic pseudoaneurysm
- Post-surgical pseudoaneurysm
- Saccular aneurysm
- Contained rupture
- Penetrating ulcer
- Patient's vascular dimensions must be in the range that can be safely treated with the stent graft and extensions available to the physician at the time of the procedure.
- Patient has patent iliac or femoral arteries or acceptable retroperitoneal access via the abdominal aorta that allow endovascular access to the aneurysmal site with a 23F delivery catheter, typically used with a 25F introducer sheath
- Patient has a non-aneurysmal proximal and distal aortic neck diameter between 25 and 36 mm.
- Patient is American Society of Anesthesiology (ASA) grade 1 through 4.
- Patient has a stage of disease or condition where there is no comparable or satisfactory alternative device or therapy available for treatment; or the patient has an immediately life-threatening disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment.
- Patient is able and willing to comply with 1 month, 6 month, and 1 year follow-up, and willing to comply with annual post-treatment follow-up requirements thereafter.
- Patient or patient's legal representative understands and has signed an Informed Consent.
Exclusion Criteria:
- The stent graft would have to be positioned such that there would be no flow to an artery, major branch artery or major branch arteries which supply the spinal cord.
- The patient has congenital abnormalities in which the placement of the stent graft will cause occlusion of major arterial flow. Such abnormalities should be evaluated prior to treatment.
- Patient is pregnant.
- Patient is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.
- Patient has connective tissue disease.
- Patient has a hypercoagulability disorder.
- Patient is in acute renal failure.
- Patient has active systemic infection.
- Patient is less than 18 years old.
- Patient has less than a one-year life expectancy.
- Patient is participating in another research study involving an investigational agent for the treatment of Descending Thoracic Aortic Aneurysms.
- Patient has other medical, social or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
- Patient is unwilling or unable to return for or comply with follow-up visit schedules.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00802984
Locations
| United States, California | |
| Stanford University School of Medicine | |
| Stanford, California, United States, 94305 | |
Sponsors and Collaborators
Stanford University
Investigators
| Principal Investigator: | Christopher K Zarins MD | Stanford University |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00802984 History of Changes |
| Other Study ID Numbers: | SU-11092007-868, IRB Protocol Number 77836 |
| Study First Received: | December 4, 2007 |
| Last Updated: | December 12, 2008 |
| Health Authority: | United States: Food and Drug Administration USA:External Monitoring Entity |
Additional relevant MeSH terms:
|
Aneurysm Aortic Aneurysm Aortic Aneurysm, Thoracic |
Vascular Diseases Cardiovascular Diseases Aortic Diseases |
ClinicalTrials.gov processed this record on May 21, 2013